Table 1.
Baseline characteristics of the participants enrolled in the 17 individual participant dataset studies
| Number of studies | Testosterone treatment group | Placebo group | ||
|---|---|---|---|---|
| Demographics | ||||
| Age, years | 16 | 64·5 (11·0); 1724 | 65·3 (10·8); 1656 | |
| Body-mass index, kg/m2 | 17 | 30·3 (4·7); 1746 | 30·2 (4·5); 1677 | |
| Ethnicity | 6 | .. | .. | |
| Caucasian | .. | 915/1046 (87·5%) | 888/1014 (87·6%) | |
| Asian | .. | 63/1046 (6·0%) | 62/1014 (6·1%) | |
| Black or African American | .. | 16/1046 (1·5%) | 12/1014 (1·2%) | |
| Other | .. | 9/1046 (0·9%) | 7/1014 (0·7%) | |
| Missing | .. | 43/1046 (4·1%) | 45/1014 (4·4%) | |
| Smoking status | 10 | .. | .. | |
| No | .. | 838/943 (88·9%) | 756/867 (87·2) | |
| Yes | .. | 103/943 (10·9%) | 107/867 (12·3%) | |
| Missing | .. | 2/943 (0·2%) | 4/867 (0·5%) | |
| Hormone concentrations | ||||
| Albumin, g/L | 9 | 42·6 (3·2); 817 | 42·7 (3·1); 783 | |
| Estradiol, pmol/L | 8 | 80·8 (38·6); 782 | 77·1 (33·6); 710 | |
| Follicle stimulating hormone, IU/L | 8 | 14·7 (16·7); 711 | 14·2 (16·0); 683 | |
| Luteinising hormone, IU/L | 8 | 6·0 (5·6); 435 | 6·3 (5·6); 362 | |
| Sex hormone binding globulin, nmol/L | 15 | 33·8 (16·6); 1256 | 32·7 (16·2); 1190 | |
| Cardiovascular reported medical history | ||||
| Unspecified | 1 | 13/45 (28·9%) | 5/43 (11·6%) | |
| Angina | 1 | 5/21 (23·8%) | 5/19 (26·3%) | |
| Coronary heart disease | 7 | 95/803 (11·8%) | 82/771 (10·6%) | |
| Myocardial infarction | 6 | 81/970 (8·4%) | 83/964 (8·6%) | |
| Arrhythmia | 6 | 36/713 (5·0%) | 25/677 (3·7%) | |
| Peripheral vascular disease | 4 | 12/500 (2·4%) | 9/472 (1·9%) | |
| Atherosclerosis | 3 | 16/531 (3·0%) | 7/527 (1·3%) | |
| Heart failure | 6 | 13/624 (2·1%) | 3/591 (0·5%) | |
| Valvular heart disease | 4 | 2/586 (0·3%) | 9/55 (16·4%) | |
| Stable angina | 3 | 4/530 (0·8%) | 8/533 (1·5%) | |
| Aortic aneurysm | 2 | 2/379 (0·5%) | 5/376 (1·3%) | |
| Unstable angina | 2 | 0/513 | 1/508 (0·2%) | |
| Cardiac arrest | 1 | 0/113 | 1/110 (0·9%) | |
| Other medical conditions | ||||
| Cerebrovascular reported medical history | 8 | 37/1139 (3·2%) | 58/1085 (5·3%) | |
| Diabetes* | 12 | 432/1574 (27·4%) | 402/1492 (26·9%) | |
| Prostate cancer | 17 | 0/1750 | 0/1681 | |
| Sexual function | ||||
| IIEF-15 | 5 | .. | .. | |
| Total | .. | 33·47 (20·65); 800 | 31·11 (20·84); 818 | |
| Erectile function | .. | 13·12 (10·03); 814 | 12·02 (10·00); 838 | |
| Orgasmic function | .. | 5·28 (3·91); 820 | 4·76 (4·02); 841 | |
| Sexual desire | .. | 5·18 (2·12); 819 | 5·03 (2·12); 839 | |
| Intercourse satisfaction | .. | 5·27 (5·00); 818 | 4·65 (4·96); 844 | |
| Overall satisfaction | .. | 4·65 (2·48); 808 | 4·59 (2·52); 826 | |
| IIEF-5 | 5 | 14·66 (7·16); 273 | 14·74 (7·01); 206 | |
| Androgen deficiency in the aging men | 1 | 4·06 (2·21); 113 | 3·69 (2·43); 110 | |
| Physiological marker | ||||
| Testosterone, nmol/L | 16 | 9·21 (2·85); 1387 | 9·21 (2·83); 1318 | |
| Free testosterone, pmol/L | 12 | 196·02 (66·46); 120 | 198·92 (70·87); 116 | |
| Fasting glucose, mmol/L | 12 | 6·55 (2·18); 1421 | 6·66 (2·36); 1353 | |
| Cholesterol, mmol/L | 15 | 4·71 (1·12); 1670 | 4·73 (1·10); 1606 | |
| Low-density lipoproteins, mmol/L | 15 | 2·81 (1·02); 1644 | 2·78 (1·00); 1584 | |
| High-density lipoproteins, mmol/L | 15 | 1·20 (0·36); 1664 | 1·21 (0·39); 1599 | |
| Triglycerides, mmol/L | 15 | 1·87 (1·39); 1653 | 1·91 (1·50); 1584 | |
| Haemoglobin, g/L | 14 | 145·26 (12·64); 160 | 144·30 (12·89); 151 | |
| HbA1c (%) | 10 | 6·35 (1·08); 1067 | 6·36 (1·12); 1059 | |
| Haematocrit (%) | 16 | 43·29 (3·68); 1694 | 42·99 (3·83); 1621 | |
| Systolic blood pressure, mm Hg | 12 | 133·13 (17·30); 130 | 133·52 (16·62); 127 | |
| Diastolic blood pressure, mm Hg | 12 | 77·21 (10·74); 1300 | 77·08 (10·72); 1274 | |
Data are mean (SD) with number of participants, or n/N (%). IIEF=International Index of Erectile Function.
*
Type 1, 2, and unknown type.